Cancer cells often evade anti-tumor immune responses by upregulating inhibitory molecules such as cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), as well as suppressive cytokines. This evidence concerns the gene CTLA4 and neoplasm.